ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Imfinzi Trial Does Not Meet Primary Endpoint americanpharmaceuticalreview
February 10, 2021The KESTREL Phase III trial for AstraZeneca’s Imfinzi (durvalumab) did not meet the primary endpoint of improving overall survival (OS) versus the EXTREME treatment regimen (chemotherapy plus cetuximab), a standard of care ... -
Extreme Eating Habits Could Be an Early Clue to Autism drugs
July 24, 2019Lots of kids are picky eaters. But when eating habits in young children are extreme, it could be a sign of?autism, researchers say.
Pharma Sources Insight January 2025
